Vectura is focused on delivering inhaled product development services to pharmaceutical and biotech customers globally.

The company has a unique service offering with proven expertise and capabilities, validated formulation and device technologies, and a track record of helping partners bring products to market.

~300

new inhaled molecules in development

~33%

of molecules focused on non-respiratory diseases where inhaled route offers benefits

70%

of inhaled assets in development are
pre-Phase II

87%

of projects in development with small and medium companies

~30-35%

of projects outsourced, with growing trend (40-45% over the next 5 years)2

Source: Global Data pipeline analysis (July 2019) – “Respiratory” includes infectious disease assets. Small & medium-sized respiratory companies excludes companies with significant in-house inhalation capabilities: Astra Zeneca, GSK, Bayer, Novartis, BI, Pfizer, Chiesi, Orion.
1 Contract development and manufacturing organisation
2 Source: Expert interviews (n=20) and expert survey (n=35) based on a sample of executives from CDMOs, Pharmaceutical and med tech companies